Cite this article
Clinical significance of inflammatory markers of bacterial infection in critically ill patients with COVID-19 after treatment with anti-inflammatory and immunomodulatory drugs: a complex new scenario
Daniele Roberto Giacobbe1,2,*, Lorenzo Ball3,4, Laura Magnasco1, Chiara Dentone1, Denise Battaglini3,5, Chiara Robba3,4, Paolo Pelosi3,4, Matteo Bassetti1,2
1 Infectious Diseases Unit, San Martino Policlinico Hospital, IRCCS for Oncology and Neuroscience, 16132 Genoa, Italy
2 Department of Health Sciences (DISSAL), University of Genoa, 16132 Genoa, Italy
3 Anesthesia and Intensive Care, San Martino Policlinico Hospital, IRCCS for Oncology and Neuroscience, 16132 Genoa, Italy
4 Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, 16132 Genoa, Italy
5 Department of Medicine, University of Barcelona, 08007 Barcelona, Spain
*Correspondence: firstname.lastname@example.org (Shantipriya Parida)
Front. Biosci. (Landmark Ed) 2021, 26(9), 405–408; https://doi.org/10.52586/4954
Submitted: 6 September 2021 | Revised: 13 September 2021 | Accepted: 17 September 2021 | Published: 30 September 2021
Copyright: © 2021 The Author(s). Published by BRI.
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
No abstract present.